secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131979
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OraSure responds to Altai Capital, citing 40% TSR outperformance under CEO; $199M cash; product catalysts ahead
--------------------------------------------------------------------------------

- Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
- Cash balance of $199M, no debt; $40M share repurchase program initiated in 2025 at avg price $2.85.
- Gross margin improved 260bps over 3 years to 43%; SG&A reduced 37% to $73.8M; workforce cut ~40%.
- Near-term catalysts: Colli-Pe urine collection device (~$0.5B TAM) and Sherlock CT/NG self-test (~$1.5B TAM).
- Expects operating cash flow breakeven entering 2027; new products launching in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000119312526131979/0001193125-26-131979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000119312526131979/d138279d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer